Skip to content

Biological characteristics of sensitization characterization in patients with chronic colitis

Biological characteristics of sensitization characterization in patients with chronic colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000126
Enrollment
Unknown
Registered
2024-07-16
Start date
2024-07-26
Completion date
Unknown
Last updated
2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic colitis

Interventions

Patients with chronic colitis:Skin sampling

Sponsors

shaaxi University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with chronic colitis observation group: (1) chronic colitis diagnostic criteria of mild and moderate patients (that is, clinical manifestations of repeated abdominal pain, diarrhea loose stool (or constipation) , stool does not contain or only a small amount of blood, mucus, no or mild systemic symptoms: colonoscopy can be seen local congestion, edema or scattered erythema, erosion; colonic mucosa pathological examination showed chronic inflammatory changes)(2) gender is not limited, age 18-65 years; (3) willing to participate in the trial and signed informed consent; note: Patients who met the above three criteria were included in the study. The healthy subjects were as follows: (1) no chronic colitis or gastrointestinal disease, (2) no gender limitation, 18-65 years old, (3) willing to participate in the trial and sign the informed consent form; Note: Patients who met the above 3 criteria were included in this study.

Exclusion criteria

Exclusion criteria: (2) previous myocardial infarction, severe heart failure, valvular heart disease, serious arrhythmias, primary cardiomyopathy, blood diseases; Patients with severe cerebrovascular disease, pregnancy, lactation, mental illness, intestinal tuberculosis, bacterial dementia, radiation colitis, malignant tumor, etc. (5) the patients with bleeding tendency or scar constitution, blood diseases, (6) the patients with skin ulcer or severe infection in the sensitive parts, (7) the patients who participated in other clinical trials. Note: any compliance with any of the above provisions shall be excluded. Healthy controls: (1) patients with previous myocardial infarction, severe heart failure, valvular heart disease, severe arrhythmias, primary cardiomyopathy, blood disorders, and other severe cerebrovascular disease; (2) pregnant women, lactating women and those with mental diseases who can not cooperate, (3) patients with intestinal tuberculosis, bacillary dysentery and malignant tumor, (4) patients with fever symptoms that affect heat sensitivity detection, (3) patients with intestinal tuberculosis, bacillary dysentery and malignant tumor (5) patients with skin diseases affecting shape-sensitive detection; (6) patients with skin ulcer or severe infection at the sensitive site; (7) patients with bleeding tendency or scar constitution; (8) patients who participated in other clinical trials. Note: Patients who meet any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
The main indexes were 5-HT, TRPV1, CGRP and so on;

Countries

China

Contacts

Public ContactQiao haifa

shaaxi University of Traditional ChineseMedicine

1511006@sntcm.edu.cn18220046518

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026